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Summary
Background Eﬀ ective targeted therapy for sepsis requires an understanding of the heterogeneity in the individual host 
response to infection. We investigated this heterogeneity by deﬁ ning interindividual variation in the transcriptome of 
patients with sepsis and related this to outcome and genetic diversity.
Methods We assayed peripheral blood leucocyte global gene expression for a prospective discovery cohort of 265 adult 
patients admitted to UK intensive care units with sepsis due to community-acquired pneumonia and evidence of 
organ dysfunction. We then validated our ﬁ ndings in a replication cohort consisting of a further 106 patients. We 
mapped genomic determinants of variation in gene transcription between patients as expression quantitative trait 
loci (eQTL).
Findings We discovered that following admission to intensive care, transcriptomic analysis of peripheral blood 
leucocytes deﬁ nes two distinct sepsis response signatures (SRS1 and SRS2). The presence of SRS1 (detected in 108 
[41%] patients in discovery cohort) identiﬁ es individuals with an immunosuppressed phenotype that included 
features of endotoxin tolerance, T-cell exhaustion, and downregulation of human leucocyte antigen (HLA) class II. 
SRS1 was associated with higher 14 day mortality than was SRS2 (discovery cohort hazard ratio (HR) 2·4, 95% CI 
1·3–4·5, p=0·005; validation cohort HR 2·8, 95% CI 1·5–5·1, p=0·0007). We found that a predictive set of seven 
genes enabled the classiﬁ cation of patients as SRS1 or SRS2. We identiﬁ ed cis-acting and trans-acting eQTL for key 
immune and metabolic response genes and sepsis response networks. Sepsis eQTL were enriched in endotoxin-
induced epigenetic marks and modulated the individual host response to sepsis, including eﬀ ects speciﬁ c to SRS 
group. We identiﬁ ed regulatory genetic variants involving key mediators of gene networks implicated in the hypoxic 
response and the switch to glycolysis that occurs in sepsis, including HIF1α and mTOR, and mediators of endotoxin 
tolerance, T-cell activation, and viral defence.
Interpretation Our integrated genomics approach advances understanding of heterogeneity in sepsis by deﬁ ning 
subgroups of patients with diﬀ erent immune response states and prognoses, as well as revealing the role of underlying 
genetic variation. Our ﬁ ndings provide new insights into the pathogenesis of sepsis and create opportunities for a 
precision medicine approach to enable targeted therapeutic intervention to improve sepsis outcomes.
Funding European Commission, Medical Research Council (UK), and the Wellcome Trust.
Copyright © Davenport et al. Open Access article distributed under the terms of CC BY.
Introduction
A clinical diagnosis of sepsis identiﬁ es a heterogeneous 
population of patients with a dysregulated systemic 
inﬂ ammatory host response to infection in the presence 
of organ dysfunction.1 Substantial individual variation in 
this response restricts therapeutic options and is a major 
contributing factor in the failure of clinical trials of 
immunomodulatory treatments for sepsis.2,3 The 
dynamic nature of the response and the importance of 
both hyperinﬂ ammatory and immunosuppressed states 
is now recognised, but eﬀ ective biomarkers to enable 
targeted therapy appropriate to the immune response 
state of the individual at the time of intervention remain 
elusive.4
The existence of genetic associations with susceptibility 
to and outcomes of infectious diseases, including sepsis, 
suggests a role for host genomic variation in the 
heterogeneity seen among patients with sepsis.5,6 
However the challenges of deﬁ ning disease phenotypes 
and establishing the functional signiﬁ cance of any 
genetic associations have so far limited such studies. 
Most associations involve DNA sequence variants in 
non-coding DNA for which regulatory eﬀ ects on gene 
expression have been proposed. To deﬁ ne genes 
modulated by genetic variation and to identify speciﬁ c 
functional regulatory polymorphisms, associations 
between genetic variants (usually single-nucleotide 
polymorphisms [SNPs]) and diﬀ erences in gene 
expression between individuals can be mapped as 
expression quantitative trait loci (eQTL).7 In leucocytes 
from healthy volunteers, we have shown that genomic 
variants modulate diﬀ erences in gene expression 
between individuals, including the response to innate 
immune stimuli such as lipopolysaccharides,8 but their 
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functional signiﬁ cance in most disease states, including 
sepsis, is unknown. In sepsis, an acute severe illness 
associated with profound alterations in physiological, 
metabolic, and immune function, the mapping of eQTL 
would enable interrogation of associations involving the 
host immune response and diverse signalling pathways.
In this study, we investigate the genomic landscape of 
sepsis due to community-acquired pneumonia, the most 
common cause of sepsis, in adult patients after admission 
to the intensive care unit (ICU). We ﬁ nd evidence of 
transcriptional signatures soon after ICU admission that 
provide information about the immune response state of 
an individual patient and their prognosis. We further 
investigate interindividual heterogeneity in the 
transcriptomic response to sepsis by use of an eQTL 
mapping approach and identify context-speciﬁ c regulatory 
genetic variants involving gene networks central to the 
pathogenesis of sepsis. 
Methods
Participants
We recruited patients to the discovery and validation 
cohorts as part of the UK Genomic Advances in Sepsis 
(GAinS) study (NCT00131196) from 29 participating 
ICUs (appendix 1 p 20) between Feb 1, 2006, and Feb 20, 
2014. Ethics approval was granted by national ethics 
committees and locally approved for individual 
participating centres. After obtaining informed consent 
from the patient or their legal representative, we 
enrolled adult patients (aged >18 years) who were 
admitted to the ICU with sepsis due to community-
acquired pneumonia (appendix 1 p 2). We analysed gene 
expression for 270 patients in the discovery cohort and 
114 patients in the validation cohort. The independent 
validation cohort consisted of patients with sepsis due 
to community-acquired pneumonia who were 
prospectively recruited to GAinS with the same 
inclusion and exclusion criteria as the discovery cohort. 
Equal numbers of survivors and non-survivors were 
selected for gene expression proﬁ ling in the validation 
cohort to maximise informativeness for outcome. The 
Acute Physiology and Chronic Health Evaluation II 
(APACHE II) scores on admission and the Sequential 
Organ Failure Assessment (SOFA) scores on days 1, 3, 
and 5 were calculated from data entered into the 
electronic case report form (eCRF) by the local 
investigators.9,10
Procedures
We obtained samples for gene expression proﬁ ling by 
rapidly isolating the total blood leucocyte population 
from whole blood samples (about 10 mL) taken following 
Research in context
Evidence before this study
We searched PubMed for articles published before Sept 1, 2015, 
using the terms “sepsis” OR “severe sepsis” OR “septic shock” 
AND “gene expression proﬁ ling” OR “transcriptomic” OR 
“microarray analysis”. We did a second search with the terms 
“sepsis” AND “eQTL” OR “expression quantitative trait” OR 
“regulatory variant”. We only considered peer-reviewed, English 
language reports. We identiﬁ ed 34 studies done in humans that 
examined the sepsis response in circulating leucocytes and 
peripheral blood. Of these studies, 12 focused on paediatric or 
neonatal sepsis. A further 19 involved small sample sizes 
(<100 patients), and the remainder combined data from 
previously published cohorts. Additionally, most recruited a 
heterogeneous patient cohort in terms of cause of sepsis. 
Several studies have aimed to develop diagnostic or prognostic 
predictive models, as well as for the subclassiﬁ cation of 
patients, using gene expression in paediatric sepsis. Reviews 
summarise the relatively low level of concordance across 
transcriptomic proﬁ ling studies of sepsis and suggest that these 
discrepancies are partly due to the use of underpowered, 
heterogeneous cohorts. The identiﬁ cation of regulatory 
variants through eQTL mapping has previously focused on cells 
and tissues from healthy individuals including whole blood, 
diﬀ erent immune cell types, and immune-relevant conditions 
of cellular activation. We identiﬁ ed no published studies that 
used eQTL mapping in the context of a severe, acute illness 
such as sepsis.
Added value of this study
We present data for large discovery and validation cohorts of 
patients with sepsis resulting from a single, well-deﬁ ned cause. 
We identiﬁ ed two distinct patient clusters within these cohorts 
based on global gene expression soon after admission to 
intensive care, one of which shows an immunosuppressed 
phenotype and is associated with higher early mortality. We 
developed a classiﬁ cation model based on the expression of a 
predictive gene set, which we validated in a prospectively 
recruited cohort. Cluster membership could not be accurately 
predicted on the basis of clinical covariates. We also show that 
underlying genetic variation aﬀ ects the individual immune 
response transcriptomic signature in the context of disease. Our 
integrated, translational genomics approach enhances 
phenotypic resolution, and reveals opportunities for precision 
medicine.
Implications of all the available evidence
Our study and others show the substantial degree of 
heterogeneity in the sepsis response, demonstrating the need 
for improved patient stratiﬁ cation and a precision medicine-
based approach to management. The diﬀ erences we found 
between the sepsis response groups have important 
therapeutic implications, including for the development of 
novel interventions, identiﬁ cation of high risk patients, and 
individually targeted therapy, and for the conduct of clinical 
trials. 
See Online for appendix 1
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admission to ICU by use of the LeukoLOCK (Thermo 
Fisher Scientiﬁ c, Waltham, MA, USA) depletion ﬁ lter 
technology (appendix 1 p 2). We puriﬁ ed total RNA and 
used Illumina Human-HT-12 version 4 Expression 
BeadChips with 47 231 probes (Illumina, San Diego, CA, 
USA) to do genome-wide transcription proﬁ ling for the 
ﬁ rst available sample taken following ICU admission for 
each of 270 patients in the discovery cohort and 
114 patients in the validation cohort (appendix 1 p 2). We 
puriﬁ ed genomic DNA from whole blood samples 
(appendix 1 p 3) and genotyped individuals in the 
discovery cohort with Illumina HumanOmniExpress 
BeadChips (730 525 SNPs; Illumina, San Diego, CA, 
USA).
Bioinformatics and statistical analysis
After background subtraction, we used the variance 
stabilisation and normalisation method to transform and 
normalise the microarray data (appendix 1 p 2). We 
removed ﬁ ve samples from the discovery cohort and eight 
samples from the validation cohort because they failed 
quality control (appendix 1 p 2). We did diﬀ erential gene 
expression analysis for 26 185 probes using limma 
(R package; appendix 1 p 3). We investigated for 
enrichment of biological pathways and functions, and for 
upstream regulators, using Ingenuity Pathway Analysis 
(IPA; Qiagen, Redwood City, CA, USA).
After quality control, we investigated interindividual 
heterogeneity in the sepsis leucocyte transcriptome in 
the discovery cohort of 265 patients by doing 
unsupervised hierarchical cluster analysis for the most 
variable 10% of probes. We deﬁ ned groupings of 
transcriptional sepsis response signatures (SRS) by 
agglomerative hierarchical clustering based on Ward’s 
method and Euclidean distance to initiate the appropriate 
number of groups, followed by consolidation of group 
membership using k-means (FactoMineR [R package], 
appendix 1 p 3). Increasing the number of clusters 
between two and four showed no reduction in the 
within-group sum of squares after application of the 
k-means procedure, which suggests that this range 
included the optimum number of deﬁ ned clusters in the 
dataset.
We identiﬁ ed clinical covariates or genes for use in 
prediction models by ﬁ tting a sparse response model 
suitable for high dimensional data (GeneRave 
[R package], appendix 1 p 3).11 We ﬁ tted generalised linear 
models with group membership or mortality as the 
response variable and either gene expression or clinical 
covariates as predictors. We established misclassiﬁ cation 
rates for models by use of leave-one-out cross-validation.12
We analysed two human endotoxin tolerance datasets13,14 
(appendix 1 p 3) to deﬁ ne an endotoxin tolerance gene 
signature consisting of 398 genes (false discovery rate 
[FDR] <0·05, fold change [FC] >1·5), of which 331 were 
also measured in the patients with sepsis. We assessed 
enrichment of this signature in the genes diﬀ erentially 
expressed between SRS groups using ROAST,15 a 
rotation-based gene set test that takes account of 
directionality in addition to signiﬁ cance.
To prospectively validate our ﬁ ndings, we ﬁ rst identiﬁ ed 
a predictive gene set to deﬁ ne SRS group membership in 
the discovery cohort by ﬁ tting a sparse response model to 
the gene expression data.11 We then analysed the 
independent validation cohort by selecting all non-
survivors and an equal number of age-matched and sex-
matched survivors for gene expression proﬁ ling. After 
quality control for gene expression, we included 
54 survivors and 52 non-survivors in the analysis. We 
assigned group membership for individuals on the basis 
of the expression of the predictive gene set (appendix 1 p 2). 
Group membership and association with outcome was 
robust to the exclusion of 17 individuals with a long 
length of stay (>15 days).
We did quality control of the genotyping data at the 
sample and SNP level by use of PLINK version 1.07 
(appendix 1 p 3). We mapped eQTL using an additive 
linear model to establish associations between SNPs and 
gene expression as assayed by speciﬁ c probes (Matrix 
eQTL [R package], appendix 1 p 3). After quality control 
and processing (appendix 1 p 3), we tested 644 390 SNPs 
for association with 17 347 uniquely mapping probes in 
240 patients in the discovery cohort. eQTL were deﬁ ned 
as cis when the distance between the chromosomal 
position of the SNP and probe start site was less than 
1 Mb. eQTL with distances greater than 2·5 Mb were 
deﬁ ned as trans and we restricted the analysis of trans-
eQTL to autosomes. We did principal component 
analysis on the gene expression matrix and included the 
ﬁ rst 30 principal components of the expression data as 
covariates in the eQTL analysis to take account of SRS 
group and limit other potential confounding factors. For 
Discovery cohort 
(n=265)
Validation cohort 
(n=106)
Age (years) 62 (16) 69 (14)
Male sex 145 (55%) 79 (75%)
APACHE II score 18 (7) 23 (9)
SOFA score 6 (4) 7 (4)
Mortality
14 day 40 (15%) 42 (40%)
28 day 56 (21%) 52 (49%)
6 month 78 (29%) 56 (53%)
Infection
Gram-positive bacteria 47 (18%) 13 (12%)
Gram-negative bacteria 25 (9%) 10 (9%)
Viral 25 (9%) 3 (3%)
Mechanical ventilation 191 (72%) 82 (77%)
Vasopressors 107 (40%) 46 (43%)
Data are n (%) or mean (SD) unless otherwise speciﬁ ed. APACHE II=Acute Physiology and Chronic Health Evaluation II. 
SOFA=Sequential Organ Failure Assessment on day of sampling. 
Table 1: Characteristics of patients included in the discovery and validation cohorts
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the SRS group-speciﬁ c eQTL, we included the ﬁ rst 
25 principal components. We found that incorporation 
of principal components enhanced discovery of 
cis-eQTL, consistent with previous studies (appendix 
1 p 3 and p 5).8,16,17 This approach identiﬁ ed more eQTL 
than did inclusion of speciﬁ c clinical covariates such as 
Figure 1: Transcriptomic sepsis response signatures
Unsupervised hierarchical cluster analysis for the top 10% most variable probes (n=2619) for the 265 patients in the discovery cohort (A). First three PCs plotted with 
the proportion of variance explained by each component (B); individuals are coloured by group membership based on two groups assigned with k-means. Volcano 
plot (C) of diﬀ erentially expressed probes for SRS1 versus SRS2 (red colouring shows fold change >1·5, false discovery rate <0·05). Most enriched functions, disease 
phenotypes, and predicted upstream regulators were derived from diﬀ erentially expressed genes (D). Kaplan-Meier survival plot by SRS group (95% CIs shaded) for 
(E) discovery cohort and (F) validation cohort. SRS=sepsis response group. PC=principal component.
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cell count. We deﬁ ned SRS-speciﬁ c cis-eQTL based on 
FDR less than 0·01 in one SRS group and greater than 
0·05 in the other. We compared sepsis-associated eQTL 
with an eQTL dataset from a meta-analysis of population 
controls generated from whole blood samples 
(appendix 1 p 3).17
We annotated expression-associated SNPs with 
chromatin features for lipopolysaccharide-stimulated 
monocytes previously identiﬁ ed by the Blueprint 
Consortium,18 including histone marks (H3K27ac, 
H3K4me1, and H3K4me3) and DNase I hypersensitivity 
(appendix 1 p 3). We compared the proportion of expression-
associated SNPs overlapping each mark with the proportion 
for SNPs within 1 Mb of a probe (Fisher’s exact test) and 
distance to the nearest mark (Mann-Whitney test).
Role of the funding source
The funders of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data and the ﬁ nal responsibility to submit 
for publication.
Results
We ﬁ rst investigated interpatient heterogeneity in the 
transcriptomic response to sepsis for 265 patients in the 
discovery cohort; all patients showed evidence of organ 
dysfunction based on SOFA scores during ICU admission 
and 28 day mortality was 21% (table 1, appendix 2). 
Unsupervised hierarchical cluster analysis of global gene 
expression for peripheral blood leucocytes revealed two 
distinct clusters (ﬁ gure 1A,B), which we denoted as sepsis 
response signature groups SRS1 and SRS2. 108 (41%) 
patients were assigned SRS1 and 157 (59%) patients as 
SRS2. We identiﬁ ed 3080 genes that were diﬀ erentially 
expressed between groups (FC >1·5, FDR <0·05), with 
2260 (73·4%) downregulated in SRS1 (ﬁ gure 1C; 
appendix 2). We saw no diﬀ erences between SRS groups 
in the expression of the pro-inﬂ ammatory cytokine genes 
TNF, IL6, or IL1B. However, pathway analysis of the 
diﬀ erentially expressed genes showed functional 
diﬀ erences related to T-cell activation, cell death, apoptosis, 
necrosis, cytotoxicity, and phagocyte movement. Speciﬁ c 
predicted upstream regulators of the diﬀ erentially 
expressed genes included transglutaminase II, B-cell and 
Discovery cohort Validation cohort
SRS group 1 
(n=108)
SRS group 2 
(n=157)
p value SRS group 1 
(n=37)
SRS group 2 
(n=69)
p value
Age (years) 60·2 (15·3) 62·9 (16·6) 0·18 67·8 (15·0) 69·8 (14·1) 0·52
Male sex 60 (56%) 85 (54%) 0·92* 25 (68%) 54 (78%) 0·33*
APACHE II score 19 (6·9) 18 (6·3) 0·24 25·1 (9·3) 21·3 (7·9) 0·04
SOFA score 7·9 (4·0) 5·4 (3·2) 2·1 × 10–7 8·6 (4·9) 6·7 (3·6) 0·033
Arterial pressure (lowest, mm Hg) 63·5 (10·5) 70·1 (13·6) 1·8 × 10–5 63·1 (13·2) 68·6 (10·7) 0·03
Mechanical ventilation 82 (76%) 109 (69%) 0·31* 30 (81%) 52 (75%) 0·67*
Vasopressors/inotropes 0·001* 0·07*
No dose 50 (46%) 108 (69%) 18 (49%) 42 (61%)
Low dose 1 (1%) 0 0 1 (<1%)
Medium dose 17 (16%) 10 (6%) 2 (5%) 10 (14%)
High dose 40 (37%) 39 (25%) 17 (46%) 16 (23%)
Bicarbonate (mmol/L) 23 (15·9) 27·6 (5·6) 6·9 × 10–9 21·5 (6·4) 25·4 (6·7) 0·005
Renal replacement therapy 17 (16%) 14 (9%) 0·13* 10 (27%) 6 (9%) 0·03*
Proportion of leucocytes
Polynucleocytes 0·89 (0·07) 0·82 (0·09) 9·6 × 10–12 0·88 (0·12) 0·83 (0·10) 0·03
Lymphocytes 0·06 (0·05) 0·11 (0·07) 7·2 × 10–10 0·06 (0·06) 0·10 (0·06) 0·004
Mononucleocytes 0·05 (0·04) 0·08 (0·05) 1·5 × 10–5 0·06 (0·09) 0·07 (0·06) 0·36
Platelets (×10³ cells per mL) 182·8 (91·5) 246·8 (119·4) 1·4 × 10–6 181·1 (98·7) 224·0 (105·8) 0·04
Infection
Gram-positive bacteria 24 (22%) 23 (15%) 0·16* 7 (19%) 6 (9%) 0·22*
Gram-negative bacteria 12 (11%) 13 (8%) 0·58* 6 (16%) 4 (6%) 0·16*
Viral 8 (7%) 17 (11%) 0·48* 0 3 (4%) 0·50*
Mortality
14 day 24 (22%) 16 (10%) 0·005† 22 (59%) 20 (29%) 0·0007†
28 day 29 (27%) 27 (17%) 0·037† 24 (65%) 28 (41%) 0·003†
6 month 39 (36%) 39 (25%) 0·032† 25 (68%) 31 (45%) 0·004†
Data are n (%) or mean (SD) unless otherwise speciﬁ ed. APACHE II=Acute Physiology and Chronic Health Evaluation II. SOFA=Sequential Organ Failure Assessment (score on 
day of sampling). Statistical analysis t test unless otherwise speciﬁ ed. *χ² test. †Log-rank test. SRS=sepsis response signature.
Table 2: Characteristics of patients included in the discovery and validation cohorts by SRS groups
See Online for appendix 2
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T-cell receptor complexes, SATB1, and GM-CSF (ﬁ gure 1D, 
appendix 1 p 6, appendix 2).
We noted that SRS group membership was associated 
with outcome; speciﬁ cally, SRS1 was signiﬁ cantly 
associated with higher early mortality (14 day mortality 
22% for SRS1 vs 10% for SRS2, hazard ratio (HR) 2·4, 
95% CI 1·3–4·5, p=0·005; ﬁ gure 1E) and indicators of 
more severe illness, but not age, sex, or microbiology 
(table 2, appendix 2). In view of the diﬀ erences that 
existed in white cell counts between patients with SRS1 
and SRS2 (table 2), we also carried out diﬀ erential gene 
expression analysis taking account of this (appendix 2). 
Pathway analysis showed that the enriched functions that 
we identiﬁ ed between SRS groups remained. We next 
investigated the extent to which clinical features might 
be predictive of SRS group (appendix 2). Any clinical 
covariate alone or in combination showed limited eﬃ  cacy 
in prediction models for SRS group membership 
(misclassiﬁ cation rates using the most informative 
selected set of clinical covariates or SOFA or APACHE II 
scores, were 19·6%, 34·0%, and 41·1%, respectively, 
appendix 2). Similarly, the timing of sampling in relation 
to ICU admission was not predictive of SRS group 
membership (misclassiﬁ cation rate 40%).
Key mediators of endotoxin tolerance were diﬀ erentially 
expressed between SRS groups, including increased 
expression of negative regulators of TLR signalling such 
as IRAK3 and TOLLIP in patients with SRS1 (appendix 2). 
To further investigate the possible association with 
endotoxin tolerance, we used published data from 
Figure 2: Overview of diﬀ erentially expressed genes between SRS groups involving HLA and T-cell activation
Red shading shows upregulation and green shading shows downregulation of genes (FC>1·5, FDR<0·05) for SRS1 versus SRS2. Solid lines show direct association, dashed lines show indirect 
association. SRS=sepsis response signature. FC=fold change. FDR=false discovery rate. MHC=major histocompatibility complex.
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endotoxin-naive and endotoxin-exposed (primed) 
peripheral blood mono nuclear cells to deﬁ ne an 
endotoxin tolerance gene expression signature of 
331 genes (FDR <0·05, FC >1·5).13,14 We detected 
signiﬁ cant enrichment (p<1 × 10–⁵) of this endotoxin 
tolerance signature in genes diﬀ erentially expressed in 
SRS1 relative to SRS2 (appendix 2).
We identiﬁ ed downregulation of human leucocyte 
antigen (HLA) class II genes and most genes implicated 
in T-cell activation in patients with SRS1 (ﬁ gure 2, 
appendix 1 p 6). These downregulated genes included 
CD247, the main signal transduction element in the 
T-cell antigen receptor complex, and other gene 
signatures of T-cell exhaustion. Gene network analysis 
also showed diﬀ erences associated with the hypoxic 
response, NF-κB, apoptosis, and histones (ﬁ gure 3A, 
appendix 1 pp 7–9).
We next aimed to validate the SRS signature and 
observed relationship with outcome. We identiﬁ ed seven 
genes (DYRK2, CCNB1IP1, TDRD9, ZAP70, ARL14EP, 
MDC1, and ADGRE3) that were predictive of SRS group 
membership in the discovery cohort, with a 
misclassiﬁ cation rate of 3·8% as established with leave-
one-out cross-validation. We then assigned group 
membership for the 106 patients in the validation cohort 
on the basis of expression of the seven gene set (table 1, 
appendix 2). Of these 106 patients, 37 (35%) were assigned 
SRS1 and 69 (65%) SRS2. In this validation cohort, we 
found that SRS group membership was again associated 
with outcome, in particular SRS1 with early mortality 
(14 day mortality was 59% for SRS1 vs 29% for SRS2, 
HR 2·8, 95% CI 1·5–5·1, p=0·0007; table 2, ﬁ gure 1F), 
which supported our ﬁ ndings from the discovery cohort. 
On genome-wide analysis, we noted a strong correlation in 
diﬀ erential gene expression between SRS groups in the 
discovery and validation cohorts (r²=0·82, p<2·2 × 10–¹⁶; 
appendix 1 p 10). Pathway analysis of diﬀ erential gene 
expression similarly showed high concordance of enriched 
functions, including for gene signatures related to 
endotoxin tolerance and T-cell exhaustion, regulators, and 
gene networks (ﬁ gure 1D, appendix 1 pp 6–9). We also 
detected a strong correlation (r²=0·84, p<2·2 × 10–¹⁶) 
between SRS groups in the validation cohort assigned with 
the seven gene signature and groups deﬁ ned by 
hierarchical cluster analysis (appendix 1 p 11).
In view of our ﬁ nding that gene expression signatures 
can deﬁ ne SRS groups that are informative for outcome, 
we compared this approach with models that use gene 
expression to predict individual mortality based on 
signatures generated with survival as a phenotype. We 
Figure 3: Diﬀ erentially expressed networks between SRS
The network with the lowest p value (p=1 × 10–35) identiﬁ ed from diﬀ erential 
expression analysis of SRS1 versus SRS2 in the discovery cohort included 
35 genes, with HIF1A and EPAS1 as nodes (A). Log FC shown with FDR. Sepsis 
cis-eQTL aﬀ ecting genes in hypoxia network (B). Presence of cis-eQTL shown by 
red molecules with p values. eQTL=expression quantitative trait loci. SRS=sepsis 
response signature. FC=fold change. FDR=false discovery rate.
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noted that models that used the most informative 
combinations of gene expression alone (misclassiﬁ cation 
rate 10·9% for 14 day survival and 16·2% for 28 day 
survival) performed better than did the most informative 
combinations of clinical covariates (misclassiﬁ cation 
rate 14% and 21·1%, respectively) in the discovery cohort 
(appendix 2). However when we tested the best 
predictive gene set for 14 day mortality in the validation 
cohort, the misclassiﬁ cation rate was high at 34% 
(appendix 2).
We then proceeded to investigate genomic modulators 
of sepsis. We proposed that individual heterogeneity in 
the transcriptomic response to sepsis might be 
modulated by genetic variation, and that such regulatory 
variants might only functionally modulate gene 
expression in the disease context of sepsis. To test this 
hypothesis, we mapped gene expression in sepsis as a 
quantitative trait for a subset of 240 patients in the 
discovery cohort. This analysis identiﬁ ed local, probably 
cis-acting, eQTL for 3795 genes (26·7% of those tested) 
with FDR less than 5% (2378 genes with FDR <1%; 
ﬁ gure 4A, appendix 2). The median proportion of 
variance explained by the expression-associated SNP 
with the lowest p value for each probe was 9·4% (range 
6·3–75·2), but this was more than 50% for immune-
related genes such as IRF5, CLEC12A, STAT6, and 
CARD8 (appendix 2).
Cis-eQTL genes (FDR <0·01) in patients with sepsis 
were signiﬁ cantly enriched for disease-relevant canonical 
pathways, including PI3K signalling, antigen 
presentation, and mitochondrial dysfunction (appendix 1 
p 12, appendix 2). The predicted upstream regulators for 
the eQTL genes that we identiﬁ ed with the lowest 
p values were key mediators of the immune response to 
sepsis, including the death receptor FAS, transcription 
factor HNF4A, IFNγ, TNF, apoptotic regulator TP53, and 
cell death regulator BID (appendix 2). eQTL were most 
enriched in gene sets associated with viral respiratory 
infection and cellular immune response (appendix 1 
p 13). These genes included cis-eQTL for TLR4 and TNF 
(ﬁ gure 4B) that we also previously reported in 
lipopolysaccharide-activated monocytes,8 as well as for 
IFNAR2, TNFRSF10B, MAPK14, NFKB1, CASP7, IL15, 
and HGF.
We next analysed trans-eQTL. We identiﬁ ed 
171 associated genes (FDR <0·05; ﬁ gure 4A, appendix 2) 
involving 380 SNPs, of which 42·6% of SNPs also show 
evidence of cis-eQTL (FDR <0·05). These eQTL included 
two known trans gene hubs proposed to be driven by 
local associations with lysozyme19 and the PAK1 inhibitor 
CRIPAK,20 in addition to a novel association with VPS18, 
which encodes a subunit of the HOPS tethering complex 
that is implicated in lysosome and endosome fusion and 
expression of genes located on six other chromosomes 
(appendix 1 p 14). We identiﬁ ed no overlap between the 
cis or trans-eQTL that we detected in sepsis and the 
association we previously found with sepsis outcome, 
which involved an intronic variant located in the FER 
gene.6
To further understand context speciﬁ city, we compared 
the cis-eQTL that we detected in sepsis with a meta-
analysis of eQTL for whole blood from 5311 individuals.17 
This comparison showed that cis-eQTL involving 
1377 genes (36·3% of all genes with eQTL, FDR <0·05 in 
patients with sepsis) were seen only in sepsis 
Figure 4: Sepsis eQTL
Circos plot (A) of, from outer rim inwards, Manhattan plot for cis-eQTL in patients with sepsis (FDR <0·05) with 
names of genes with large eﬀ ect sizes (variance explained, r2>70%) or examples of pathophysiological relevance 
shown; chromosome number; trans-eQTL (FDR<0·05) involving expression-associated SNPs also showing cis-eQTL 
(associated trans genes [orange] and SNPs [blue]). Box plots and local association plots for TLR4 and TNF (B). 
eQTL=expression quantitative trait loci. SNP=single-nucleotide polymorphism. FDR=false discovery rate.
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(appendix 1 p 15). Such eQTL were located signiﬁ cantly 
more distally from the transcriptional start site than were 
those shared with individuals without sepsis (Mann-
Whitney test p=9·4 × 10–³⁸; appendix 1 p 16), consistent 
with context-speciﬁ c eQTL being enriched at more distal 
regulatory elements.8,19,21
We next investigated whether sepsis eQTL were 
enriched in endotoxin tolerant genes and endotoxin-
induced epigenetic marks. We found that sepsis cis-
eQTL are enriched in the set of 331 endotoxin tolerant 
genes that we deﬁ ned (χ² p<0·0001). Expression-
associated SNPs were signiﬁ cantly enriched in histone 
marks for active enhancer elements (H3K4me1 and 
H3K27ac) previously identiﬁ ed in lipopolysaccharide-
treated monocytes18 compared with all SNPs within 1 Mb 
of a probe (2·91% vs 0·86%, p=2·02 × 10–²⁶) and open 
chromatin predictive of regulatory sites (ie, DNase I 
hypersensitive sites; 3·65% vs 0·79%, p=1·98 × 10–⁴⁶; 
ﬁ gure 5). These results suggest that cis-eQTL in sepsis 
are often located in regulatory genomic elements speciﬁ c 
to endotoxin-activated cells.
In the ﬁ nal phase of our analysis, we investigated the 
association between sepsis eQTL and SRS membership. 
In the genes diﬀ erentially expressed between SRS 
groups, there was evidence of enrichment for eQTL (χ² 
p<0·0001), including for genes previously implicated in 
the pathogenesis of sepsis and its treatment, such as 
IL18RAP, CCR1, CCR3, and SIRT1 (appendix 1 pp 17–18 
and appendix 2). Sepsis-associated eQTL were over-
represented in speciﬁ c pathways and networks enriched 
for genes that were diﬀ erentially expressed between SRS 
groups (appendix 1 pp 7–8). The most signiﬁ cantly 
enriched gene network identiﬁ ed by diﬀ erential gene 
expression analysis included hypoxia inducible 
transcription factors HIF1A (HIF1α) and EPAS1 (HIF2α) 
as nodal genes (ﬁ gure 3A, appendix 1 p 7). Both genes 
were upregulated in patients with SRS1 and each shows 
evidence of cis-eQTL in sepsis, together with 11 other 
genes in the network including lactate dehydrogenase A 
(LDHA; ﬁ gure 3B). We identiﬁ ed signiﬁ cant enrichment 
of eQTL in this network (χ² p=0·005).
We also discovered that MTOR was downregulated in 
patients with SRS1 and showed evidence of a sepsis 
eQTL. After mapping eQTL by SRS group, we noted that 
this association was only present in patients with SRS1 
(ﬁ gure 6A,B). We identiﬁ ed further examples of eQTL 
that were only signiﬁ cant in speciﬁ c SRS groups 
(appendix 2), including for the heat shock transcription 
factor 2 gene HSF2, for which the eQTL was restricted to 
patients with SRS1 (appendix 1 pp 17–18), and genes such 
as LAX1, TRIM44, and DDX24 for which eQTL were only 
detected in patients with SRS2 (ﬁ gure 6C,D, appendix 2).
Discussion
We propose that individual transcriptomic signatures 
that deﬁ ne the host response in sepsis will help to inform 
work establishing a precision medicine-based approach 
for sepsis management, reﬁ ne the selection of patients 
for inclusion in clinical trials, and enable the development 
of novel targeted therapies. We found that for a critically 
ill population with sepsis caused by a speciﬁ c source of 
infection (ie, community-acquired pneumonia), 
transcriptomic proﬁ ling of circulating peripheral blood 
leucocytes, which are central to the pathogenesis of 
sepsis, can deﬁ ne individual sepsis response signatures. 
One of these signatures (SRS1) identiﬁ ed a group of 
patients with features of relative immunosuppression, 
endotoxin tolerance, T-cell exhaustion, and metabolic 
derangement associated with a worse prognosis. 
Individuals with such a signature might be less able to 
eradicate infection and be susceptible to recurrent 
episodes of hospital-acquired infections and they might, 
therefore, beneﬁ t from therapy designed to boost their 
immune competence. Several such immune modulators 
Figure 5: Sepsis eQTL and epigenetic marks
Enrichment of expression-associated SNPs with the lowest p values for each gene (FDR<0·05) for sepsis cis-eQTL 
within DNase I hypersensitive sites (DNase I), and within peak intervals deﬁ ned for diﬀ erent histone modiﬁ cations 
(H3K27ac, H3K4me1, and H3K4me3), in monocytes tolerised by exposure to lipopolysaccharide for 24 h.18 p value 
shown for enrichment versus all local SNPs in terms of the proportion of expression-associated SNPs that 
overlapped with each mark (Fisher’s exact test) and distance to the nearest mark (Mann-Whitney test). FDR=false 
discovery rate. SNP=single-nucleotide polymorphism. eQTL=expression quantitative trait loci. *p<2·2 × 10–16.
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are being advocated as potential treatments for sepsis, 
including cytokines (interleukin 7, interleukin 15, 
GM-CSF, interferon γ) and co-inhibitory molecular 
blockade (eg, anti-programmed cell death receptor-1 and 
anti-B and T lymphocyte attenuator).22
Our ﬁ ndings also support the idea that relative 
immunosuppression can occur soon after the onset of 
sepsis and contributes to early mortality. These results 
were supported by our showing in a separate cohort that 
the expression of seven genes is predictive of SRS group 
membership and early mortality. Moreover we found that 
clinical covariates, alone or in combination, did not 
predict SRS groupings and that our ﬁ ndings were robust 
to analyses that take into account diﬀ erences in leucocyte 
cell count. Our results also demonstrate that the approach 
adopted by previous investigators of deﬁ ning a gene 
expression signature predictive of individual mortality 
using survival to deﬁ ne groups23,24 performed poorly in 
our replication cohort and is of little clinical utility. We 
propose that this poor performance reﬂ ects the many 
factors contributing to individual mortality in sepsis and 
contrasts with the ability of a gene expression signature 
to resolve a sepsis immune response state (as achieved 
with the SRS groups) that consistently associates with a 
worse prognosis.
Endotoxin tolerance is a crucial homoeostatic 
mechanism whereby initial endotoxin exposure results 
in a transient hyporesponsive state through epigenetic 
reprogramming and repression and induction of a set of 
genes. Our ﬁ nding that patients with SRS1 have features 
of endotoxin tolerance based on transcriptomic 
signatures is consistent with previous evidence 
suggesting that dysregulation of endotoxin tolerance 
contributes to immunosuppression and mortality in 
sepsis.25,26 Pena and colleagues,26 for example, reported 
that a gene expression signature of endotoxin tolerance 
derived ex vivo from peripheral blood mononuclear cells 
was predictive of the development of conﬁ rmed sepsis 
and organ dysfunction. Our ﬁ nding that HLA class II 
genes are downregulated in patients with SRS1 is 
consistent with previous reports of associations between 
reduced class II expression and poor outcome in sepsis,27 
while expression signatures of T-cell exhaustion 
are implicated in a recognised mechanism of 
immunosuppression in sepsis.28 We identiﬁ ed several 
predicted upstream regulators for the genes diﬀ erentially 
expressed between SRS groups that are known to be 
involved in the pathogenesis of sepsis, including 
transglutaminase II,29 GM-CSF,4 and SATB1, which is 
crucial for chromatin remodelling and cytokine gene 
expression.30
We propose that the clustering of gene expression 
patterns and outcomes that we identiﬁ ed is likely to 
represent not only the premorbid condition of the host 
(eg, age, pre-existing comorbidities), severity of the 
infection (abundance or virulence of the infecting 
organism), and stage in the natural history of the 
illness,4 but might also be modulated by genomic 
sequence variation. Identiﬁ cation of eQTL in disease-
relevant contexts is essential to understand the role of 
regulatory genetic variation in the host response given 
the context speciﬁ city of the action of such variants, 
especially in modulating the response to pathogens, as 
shown in research involving rhinovirus infection.31 We 
found evidence of sepsis eQTL that aﬀ ected speciﬁ c 
genes previously implicated in sepsis pathogenesis and 
treatment, including eQTL for IL18RAP, which encodes 
Figure 6: Sepsis eQTL and response state
SRS1-speciﬁ c eQTL for MTOR (A,B). There is reduced expression in SRS1 individuals (FC 0·85, FDR 4·9 × 10–8). SRS2-
speciﬁ c eQTL for LAX1 (C,D). LAX1 is diﬀ erentially expressed between SRS groups (0·44 FC, FDR 7·8 × 10–25). Box 
plots by allele for SRS1 and for SRS2 groups (A,C). Regional association plots (B,D). eQTL=expression quantitative 
trait loci. SRS=sepsis response signature. FC=fold change. FDR=false discovery rate.
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an accessory protein that enhances IL18-binding activity 
and is upregulated in patients with SRS1. IL18R1 has 
been proposed as a biomarker of sepsis32 and 
neutralising IL18 signalling has been advocated as a 
therapeutic intervention.33 We also detected sepsis eQTL 
involving the most signiﬁ cant disease SNP for Behcet’s 
disease,34 which we ﬁ nd modulates expression of the 
chemokine receptor genes CCR1 and CCR3, which are 
upregulated and downregulated, respectively, in patients 
with SRS1. Antagonists to CCR1 attenuate the systemic 
inﬂ ammatory response in sepsis35 and CCR3 expression 
is reduced in septic shock.36 Other examples of sepsis 
eQTL that we identiﬁ ed and were relevant to sepsis 
pathogenesis included MLKL (necroptosis), NLRC5 
(regulation of the major histocompatibility complex), 
HSPA1B (heat shock), IER3 (protection from 
apoptosis37), CTSC (granule-mediated apoptosis and 
antiviral protection38), and PADI4 (initiates neutrophil 
NETosis in sepsis, promoting host defence39).
Our pathway analysis identiﬁ ed genetic variants 
associated with the expression of genes implicated in key 
processes in the immune and metabolic response to 
infection. For example, our detection of eQTL for HIF1A, 
EPAS1, and MTOR shows how individual predisposition 
could modulate the metabolic basis of trained immunity. 
HIF1α is central to the functional reprogramming of 
monocytes in sepsis whereby tolerance, tissue 
remodelling, and antimicrobial responses are controlled,40 
while epigenetic reprogramming dependent on the 
Akt–mTOR–HIF1α pathway modulates an eﬀ ective 
immune response to sepsis in mice.41 mTOR is crucial in 
the switch to pro-inﬂ ammatory glycolysis that occurs in 
sepsis.41 Similarly, we also identiﬁ ed cis-eQTL for LDHA, 
which is responsible for the ﬁ nal step in anaerobic 
glycolysis and was signiﬁ cantly upregulated in patients 
with SRS1. We previously found that this eQTL is also 
present in monocytes but is speciﬁ c to cells treated with 
lipopolysaccharide for 24 h.8 Serum lactate is an important 
clinical biomarker associated with organ failure and 
mortality in sepsis.42 We also found that GAPDH, which 
encodes an enzyme required for glycolysis and is linked to 
sepsis-related acute lung injury,43 was signiﬁ cantly 
upregulated, consistent with a metabolic switch from 
oxidative phosphorylation to glycolysis in patients with 
SRS1,41 but with no evidence of an eQTL. Furthermore, 
SIRT1, which encodes a histone deacetylase essential to 
nuclear–mitochondrial communication during immune–
metabolic adaptation in sepsis,44 and which modulates 
epigenetic gene silencing in endotoxin tolerance, was 
downregulated in patients with SRS1 and has a sepsis cis-
eQTL.
The cis-eQTL that we identiﬁ ed for MTOR was only 
present in patients with SRS1. Other examples of such 
eQTL included HSF2, which encodes heat shock 
transcription factor 2, which is crucial to regulation of 
the heat shock response in infection, inﬂ ammation, and 
oxidative stress and has evidence of association with 
mortality in sepsis.45 By contrast, LAX1, which encodes a 
negative regulator of T-cell activation,46 showed evidence 
of eQTL only in patients with SRS2; in this case, the lead 
expression-associated SNP is also an induced eQTL in 
lipopolysaccharide-stimulated mono cytes.8 SRS2 group 
eQTL speciﬁ city was also seen for TRIM44, which 
promotes an enhanced cellular response to viral 
infection,47 and DDX24, which encodes a type I interferon-
inducible DEAD-box protein RNA-helicase modulating 
IRF7 activity.48
There are necessarily limitations to this study. We 
recognise that further work is needed to understand the 
temporal, cellular, and tissue speciﬁ cities of our ﬁ ndings. 
It will also be important to establish whether the same 
SRS can be found in patients with sepsis of diﬀ erent 
causes. Other investigators have reported the potential 
clinical utility of gene expression proﬁ ling at ICU 
admission, showing that the ratio of expression of two 
negative regulators of apoptosis (FAIM3 and PLAC8) 
could be used to assist in the rapid diagnosis of 
community-acquired pneumonia,49 while in paediatric 
patients with septic shock, transcriptomics might be 
useful for patient subclassiﬁ cation and identiﬁ cation of 
individuals who might beneﬁ t from adjunctive 
corticosteroids.50 Proteomic analysis would help to 
further validate our transcriptomic ﬁ ndings and more 
research is needed at an immunological level to 
functionally characterise the SRS phenotypes. Our 
ﬁ nding that eQTL in patients with sepsis aﬀ ect key 
mediators of disease requires further functional 
characterisation to establish causal mechanistic 
associations for speciﬁ c genetic variants and to establish 
their physiological consequences. For trans eﬀ ects at a 
distance, larger sample sizes will be needed to provide 
suﬃ  cient power to ﬁ nd additional moderate-to-small 
genetic eﬀ ects.17 We did not ﬁ nd overlap with our 
previous genome-wide association study (GWAS) of 
sepsis that had implicated the FER gene in sepsis 
outcome.6 However we noted that this gene was 
expressed at low levels in the total leucocyte population, 
and the disease-associated variant might act through 
eﬀ ects on splicing or other mechanisms. To aid 
understanding of the role of regulatory genetic variants 
in sepsis susceptibility and disease outcome, we suggest 
that further GWAS will be needed in which the disease 
phenotype is more precisely deﬁ ned, for example based 
on SRS group.
In view of the persistently high mortality associated 
with sepsis and the absence of speciﬁ c therapies,2 
advances based on modulating the septic response are 
needed urgently. Our analysis of interindividual 
variation in transcriptomic responses in a disease 
context shows that this approach can provide insights 
into the taxonomy of acute illness by improved 
phenotypic classiﬁ cation of sepsis patients. Improved 
classiﬁ cation could have potentially important 
therapeutic implications, including for the development 
Articles
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of novel interventions, identiﬁ cation of high risk 
patients, and individually targeted therapy aiming to 
modulate the dysfunctional host response.
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